Meta-analysis of Transcatheter Aortic Valve Implantation in Patients with Stenotic Bicuspid vs. Tricuspid Aortic Valve

Transcatheter aortic valve implantation (TAVI) is currently approved for the treatment of tricuspid aortic stenosis (TAS) in patients with high, intermediate, and even low risk for surgery .1 Most trials investigating the role of TAVI across various strata of risk categories have excluded patients with bicuspid aortic stenosis (BAS) due to its anatomical complexities. There is a ∼20% prevalence of BAS in patients greater than 80 years of age .2 Elderly patients with BAS represent an unique therapeutic challenge in high risk and intermediate risk strata where surgery is not feasible.

Source: The American Journal of Cardiology - January 14, 2021 Category: Cardiology Authors: Monil Majmundar, Ashish Kumar, Rajkumar Doshi, Palak Shah, Shilpkumar Arora, Mariam Shariff, Devina Adalja, Ferdinand Visco, Hossam Amin, Saraschandra Vallabhajosyula, Nageshwara Gullapalli, Samir R. Kapadia, Ankur Kalra, Sidakpal S. Panaich Tags: Original article Source Type: research